Search in the Abstract Database

Search Abstracts 2015

* = Presenting author

P195 Bone metabolic disease in Inflammatory Bowel Disease patients with past or current corticosteroid treatment

J. Miranda-Bautista*1, M.D. Perez-Valderas1, A. Caballero-Marcos2, A. Diaz-Redondo3, I. Marin-Jimenez1, L. Menchen1

1Hospital General Universitario "Gregorio Marañón", Gastroenterology Unit, Madrid, Spain, 2Hospital General Universitario , Gastroenterology Unit, Madrid, Spain, 3Hospital General Universitario , Preventive medicine and Epidemiology Service, Madrid, Spain

Background

Bone metabolic disease (BMD) is a well-known complication of inflammatory bowel disease (IBD) The aim of this study is to analyse the prevalence of BMD in a large sample of Southern European patients with IBD with past or current corticosteroid treatment, and secondary studying the clinical, metabolic and pharmacological factors that are associated with osteoporosis in this population.

Methods

We have conducted an observational, retrospective and cross-sectional study of BMD based on the first bone densitometry (DXA) in patients with IBD and previous corticosteroid therapy from our institution. Clinical charts have been systematically reviewed and the data obtained have been included. The medium T-score on hip and spine was compared with the possible factors involved in the development of osteoporosis in IBD patients.

Results

From our IBD data base we selected patients with past or current corticosteroid treatment and bone densitometry, and finally 412 were included. The average age was 47.8 (SD 14.7), with 42.5% of males. 61.2% had Crohn's Disease (CD), 36.2% Ulcerative colitis (UC), and 2.7% had Indeterminate Colitis (IC). Concerning additional previous treatments, 47% received immunomodulators (IMM), 24.6% biological therapies, 20.4% Proton Pump Inhibitors (PPI). Prior surgery was performed in 30.6% of patients. Bone metabolic disease (i. e. Hip and/or spine T score < -1 SD) was present 66% of patients, while osteoporosis (i. e. Hip and/or spine T score < -2.5 SD) was present in 21.8%. Univariate analysis was performed, and factors correlated with BMD were identified: age (p<0.000), not previous treatment with IMM (p=0.028). Factors related with osteoporosis were: age (p<.0000), type of IBD (suggesting relationship between UC and osteoporosis, p=0.017).

Conclusion

BMD is a frequent complication in IBD patients with past or current corticosteroid treatment. Special attention must be paid in early evaluation of bone density in these patients.